ReviewAging medicine (Milton (N.S.W))2025
Frontiers in Nondrug Treatment of Sarcopenia: A Review of Pathological Mechanisms and the Latest Treatment Strategies.
Review in Aging medicine (Milton (N.S.W)), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Brain-Derived Neurotrophic Factor, Sarcopenia and Digital Gait Characteristics in Older Adults: Insights Into the Brain-Muscle Axis.Journal of cachexia, sarcopenia and muscle · 2026Article
- Evaluation of the knowledge, perception, and practice of nurses regarding sarcopenia: a descriptive study.BMC geriatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia refers to the progressive decline and wasting of skeletal muscle function, typically linked to aging or as a secondary effect of various conditions, including systemic inflammation, oxidative stress, and mitochondrial dysfunction. Recent scientific research underscores that skeletal muscle function is regulated by multiple factors. These include not only physical activity, environmental exposures, and genetic tendencies, but also nutritional deficiencies. Currently, pharmacological interventions for sarcopenia remain a matter of ongoing debate; the recommended strategies for promoting muscle health center on nutritional support therapy and physical exercise. This review offers an insightful examination of the molecular pathways and Pathophysiology contributing to skeletal muscle atrophy and highlights recent progress in employing nonpharmacological approaches (particularly, nutritional supplementation and physical exercise) for its prevention and management. To provide new scientific evidence and effective strategies for the prevention and treatment of sarcopenia, help to bolster the preservation of skeletal muscle function, and improve the quality of life and health of the elderly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.